Literature DB >> 21236396

Cytomegalovirus in hematopoietic stem cell transplant recipients.

Per Ljungman1, Morgan Hakki, Michael Boeckh.   

Abstract

This article examines the clinical manifestations of and risk factors for cytomegalovirus (CMV). Prevention of CMV infection and disease are also explored. Antiviral resistance and management of CMV are examined.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Year:  2011        PMID： 21236396      PMCID： PMC3340426          DOI： 10.1016/j.hoc.2010.11.011

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN： 0889-8588            Impact factor:   3.722


  161 in total

1.  Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR.

Authors:  Michael Boeckh; MeeiLi Huang; James Ferrenberg; Terry Stevens-Ayers; Laurence Stensland; W Garrett Nichols; Lawrence Corey
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

2.  Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferon-gamma-enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation.

Authors:  Holger Hebart; Senay Daginik; Stefan Stevanovic; Ulrich Grigoleit; Andrea Dobler; Manuela Baur; Georg Rauser; Christian Sinzger; Gerhard Jahn; Juergen Loeffler; Lothar Kanz; Hans-Georg Rammensee; Hermann Einsele
Journal:  Blood       Date:  2002-05-15       Impact factor: 22.113

3.  Prospective comparison of PCR-based vs late mRNA-based preemptive antiviral therapy for HCMV infection in patients after allo-SCT.

Authors:  H Hebart; C Lengerke; P Ljungman; C V Paya; T Klingebiel; J Loeffler; S Pfaffenrath; I Lewensohn-Fuchs; L Barkholt; J Tomiuk; C Meisner; J Lunenberg; B Top; R R Razonable; R Patel; M R Litzow; G Jahn; H Einsele
Journal:  Bone Marrow Transplant       Date:  2010-06-28       Impact factor: 5.483

4.  A randomized trial of high dose polyvalent intravenous immunoglobulin (HDIgG) vs. Cytomegalovirus (CMV) hyperimmune IgG in allogeneic hemopoietic stem cell transplants (HSCT).

Authors:  P Zikos; M T Van Lint; T Lamparelli; F Gualandi; D Occhini; N Mordini; G Berisso; S Bregante; A Bacigalupo
Journal:  Haematologica       Date:  1998-02       Impact factor: 9.941

5.  Comparative analysis of CD8+ T cell responses against human cytomegalovirus proteins pp65 and immediate early 1 shows similarities in precursor frequency, oligoclonality, and phenotype.

Authors:  Naeem Khan; Mark Cobbold; Russell Keenan; Paul A H Moss
Journal:  J Infect Dis       Date:  2002-03-25       Impact factor: 5.226

6.  Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation.

Authors:  Pierre Reusser; Hermann Einsele; John Lee; Liisa Volin; Montserrat Rovira; Dan Engelhard; Jürgen Finke; Catherine Cordonnier; Hartmut Link; Per Ljungman
Journal:  Blood       Date:  2002-02-15       Impact factor: 22.113

7.  Differential initiation of innate immune responses induced by human cytomegalovirus entry into fibroblast cells.

Authors:  Laura K Juckem; Karl W Boehme; Adam L Feire; Teresa Compton
Journal:  J Immunol       Date:  2008-04-01       Impact factor: 5.422

8.  Evaluation of intervention strategy based on CMV-specific immune responses after allogeneic SCT.

Authors:  G Avetisyan; J Aschan; H Hägglund; O Ringdén; P Ljungman
Journal:  Bone Marrow Transplant       Date:  2007-08-27       Impact factor: 5.483

9.  Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity.

Authors:  Michael Boeckh; Wendy Leisenring; Stanley R Riddell; Raleigh A Bowden; Meei-Li Huang; David Myerson; Terry Stevens-Ayers; Mary E D Flowers; Terri Cunningham; Lawrence Corey
Journal:  Blood       Date:  2002-09-12       Impact factor: 22.113

10.  T cell recognition patterns of immunodominant cytomegalovirus antigens in primary and persistent infection.

Authors:  Naeem Khan; Donna Best; Rachel Bruton; Laxman Nayak; Alan B Rickinson; Paul A H Moss
Journal:  J Immunol       Date:  2007-04-01       Impact factor: 5.422
View more
  108 in total

1.  Cytomegalovirus infection according to cell source after hematopoietic cell transplantation in pediatric patients.

Authors:  Eun Sang Yi; Yae-Jean Kim
Journal:  Yonsei Med J       Date:  2012-03       Impact factor: 2.759

2.  Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen.

Authors:  Shivaprasad Manjappa; Pavan Kumar Bhamidipati; Keith E Stokerl-Goldstein; John F DiPersio; Geoffrey L Uy; Peter Westervelt; Jingxia Liu; Mark A Schroeder; Ravi Vij; Camille N Abboud; Todd A Fehniger; Amanda F Cashen; Iskra Pusic; Meagan Jacoby; Srinidhi J Meera; Rizwan Romee
Journal:  Biol Blood Marrow Transplant       Date:  2013-10-10       Impact factor: 5.742

3.  Rapid Acquisition of Cytomegalovirus-Specific T Cells with a Differentiated Phenotype, in Nonviremic Hematopoietic Stem Transplant Recipients Vaccinated with CMVPepVax.

Authors:  Corinna La Rosa; Jeffrey Longmate; Chetan Raj Lingaraju; Qiao Zhou; Teodora Kaltcheva; Nicola Hardwick; Ibrahim Aldoss; Ryotaro Nakamura; Don J Diamond
Journal:  Biol Blood Marrow Transplant       Date:  2018-12-16       Impact factor: 5.742

4.  Cytomegalovirus (CMV) Cell-Mediated Immunity and CMV Infection After Allogeneic Hematopoietic Cell Transplantation: The REACT Study.

Authors:  Roy F Chemaly; Lynn El Haddad; Drew J Winston; Scott D Rowley; Kathleen M Mulane; Pranatharthi Chandrasekar; Robin K Avery; Parameswaran Hari; Karl S Peggs; Deepali Kumar; Rajneesh Nath; Per Ljungman; Sherif B Mossad; Sanjeet S Dadwal; Ted Blanchard; Dimpy P Shah; Ying Jiang; Ella Ariza-Heredia
Journal:  Clin Infect Dis       Date:  2020-12-03       Impact factor: 9.079

5.  Low-Level Cytomegalovirus Antigenemia Promotes Protective Cytomegalovirus Antigen-Specific T Cells after Allogeneic Hematopoietic Cell Transplantation.

Authors:  George L Chen; Paul K Wallace; Yali Zhang; Joseph D Tario; Amanda C Przespolewski; Joanne Becker; Nikolaos G Almyroudis; Maureen Ross; Marcie Riches; Brahm H Segal; Liselotte Brix; Philip L McCarthy; Theresa Hahn
Journal:  Biol Blood Marrow Transplant       Date:  2020-07-25       Impact factor: 5.742

6.  The Ability of a Cytomegalovirus ELISPOT Assay to Predict Outcome of Low-Level CMV Reactivation in Hematopoietic Cell Transplant Recipients.

Authors:  Lynn El Haddad; Ella Ariza-Heredia; Dimpy P Shah; Ying Jiang; Ted Blanchard; Shashank S Ghantoji; Firas El Chaer; Danielle El-Haddad; Amrita Prayag; Lior Nesher; Katy Rezvani; Elizabeth Shpall; Roy F Chemaly
Journal:  J Infect Dis       Date:  2019-02-23       Impact factor: 5.226

7.  Human Cytomegalovirus Infection in Women With Preexisting Immunity: Sources of Infection and Mechanisms of Infection in the Presence of Antiviral Immunity.

Authors:  William J Britt
Journal:  J Infect Dis       Date:  2020-03-05       Impact factor: 5.226

8.  Immune Correlates of Protection Against Human Cytomegalovirus Acquisition, Replication, and Disease.

Authors:  Cody S Nelson; Ilona Baraniak; Daniele Lilleri; Matthew B Reeves; Paul D Griffiths; Sallie R Permar
Journal:  J Infect Dis       Date:  2020-03-05       Impact factor: 5.226

9.  Comparison of droplet digital PCR to real-time PCR for quantitative detection of cytomegalovirus.

Authors:  R T Hayden; Z Gu; J Ingersoll; D Abdul-Ali; L Shi; S Pounds; A M Caliendo
Journal:  J Clin Microbiol       Date:  2012-12-05       Impact factor: 5.948

10.  Fully automated quantification of cytomegalovirus (CMV) in whole blood with the new sensitive Abbott RealTime CMV assay in the era of the CMV international standard.

Authors:  Nathalie Schnepf; Catherine Scieux; Matthieu Resche-Riggon; Linda Feghoul; Alienor Xhaard; Sébastien Gallien; Jean-Michel Molina; Gérard Socié; Denis Viglietti; François Simon; Marie-Christine Mazeron; Jérôme Legoff
Journal:  J Clin Microbiol       Date:  2013-04-24       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.